To ultimately define the role of UBE2T germline mutations in patients with breast/ovarian cancer, we performed whole exome sequencing using the Ilumina HiSeq platform on 450 BRCA1/2 WT high-risk breast cancer patients. This evidence concerns the gene BRCA1 and breast cancer.